Introduction {#sec1_1}
============

Diabetic macular edema (DME) is one of the leading causes of vision loss in the working-age population around the world \[[@B1]\]. It is defined by abnormal collection of extracapillary fluid due to blood-retinal barrier breakdown because of increased production of inflammatory mediators and vascular permeability factors and loss of endothelial tight junctions \[[@B2], [@B3]\]. Because of its complex and multifactorial pathophysiology and chronic nature, it can necessitate ongoing and numerous therapies to maintain vision.

In the past, the standard care for DME was focal/grid laser photocoagulation, but the visual acuity gain was only modest \[[@B4], [@B5]\]. Treatments for DME are rapidly evolving, and today there are numerous alternative therapies to improve patients\' vision. Inhibitors of vascular endothelium growth factor (VEGF) are currently considered as the first-line therapy of choice for DME. Several trials have shown that frequent intravitreal injections with anti-VEGF were more effective than laser photocoagulation for the treatment of DME \[[@B6], [@B7], [@B8]\]. However, a large proportion of patients still have a poor response to anti-VEGF agents even with frequently repeated injections. In the phase III ranibizumab studies on DME (RISE and RIDE), between 30.4 and 43.2% of the patients failed to gain ≥10 letters after 3 years of treatment with 0.3 or 0.5 mg ranibizumab \[[@B6]\]. A recent analysis of protocol I data showed that about 40% of the eyes had a suboptimal early response (\<5-letter improvement) at 12 weeks, and most of these had suboptimal visual outcomes after 3 years of treatment \[[@B9]\].

Intravitreal corticosteroids have also been evaluated and shown to be effective in achieving visual gain and reduction of DME because of their ability to act on other inflammatory cytokines and pathogenic mechanisms, in addition to those associated with VEGF. Also, they can reduce the frequency of injections needed \[[@B10], [@B11]\]. The currently available intravitreal corticosteroids for the management of DME include triamcinolone (unlicensed for DME in Europe), dexamethasone (Ozurdex®; Allergan), and fluocinolone acetonide (FAc) (ILUVIEN®; Alimera Sciences). Whilst the treatment effect of dexamethasone implants lasts up to 6 months, the effect of FAc implants is up to 3 years \[[@B12]\]. The FAME study showed that approximately one-third (34%) of their patients with DME for ≥3 years who were treated with a 0.2 μg/day FAc implant experienced a ≥15-letter gain, compared with 13.4% of the sham-treated patients \[[@B11]\].

Here, we present the case report of a patient with recurrent DME uncontrolled by several medical and surgical treatments that showed an anatomical and functional response after treatment with a single intravitreal FAc implant.

Case Report {#sec1_2}
===========

The patient was a 61-year-old Caucasian woman with type 2 diabetes over the previous 25 years who always had good metabolic control (HbA~1c~ \<7.5%). She was first diagnosed in November 2004 with bilateral incipient diabetic retinopathy. Almost 4 years after first presentation, she had decreased vision (3/10 in the right eye and 4/10 in the left eye) due to the development of cystoid macular edema (CME), which was treated at that time with focal argon grid laser in both eyes. Her best corrected visual acuity (BCVA) and CME did not improve (Fig. [1](#F1){ref-type="fig"}). Subsequently, the patient was treated by intravitreal injection of triamcinolone acetonide into both eyes, with improvement of CME. In 2010, panretinal photocoagulation was started in both eyes due to proliferative diabetic retinopathy.

Despite good glycemic control, the patient\'s DME and proliferative retinopathy continued to develop, with decreasing BCVA. In August 2011, the patient\'s CME increased and BCVA decreased again (1/10 in both eyes). She underwent multiple triamcinolone acetonide injections into both eyes with partial and transitory responses (Fig. [2](#F2){ref-type="fig"}). A transient increase in intraocular pressure (IOP) was observed after intravitreal triamcinolone injection.

In November 2012, the left eye underwent pars plana vitrectomy combined with phacoemulsification due to vitreous hemorrhage and cataract development, respectively. After the surgical procedure, the development of central retinal atrophy (central foveal thickness of 195 µm) and a BCVA of 0.5/10 in the left eye were verified, results which remained stable over the follow-up period. The right eye also underwent phacoemulsification due to cataract development, combined with intravitreal triamcinolone. Postoperatively, the right eye\'s BCVA increased to 6/10 and the macula became dry.

In September 2013, the right eye developed CME again and the BCVA dropped to 2/10. The patient received a loading dose of 3 intravitreal injections of ranibizumab with an increase in BCVA to 5/10, but with recurrence of CME 4 months later. Up to 2015, alternate intravitreal injections of ranibizumab and triamcinolone acetonide were performed on the right eye, without sustained functional or anatomical results.

In September 2015, an FAc intravitreal implant was placed in the right eye, with resolution of the CME (the central foveal thickness decreased from 488 µm prior to the injection to 198 µm after treatment) and an increase in BCVA (from 2/10 to 6/10 after the injection) 1 month later, results that remain stable 12 months later (Fig. [3](#F3){ref-type="fig"}). Table [1](#T1){ref-type="table"} summarizes the treatments performed on the right eye for DME, and the respective outcomes, from the diagnosis of diabetic retinopathy to the present date.

As in the last year intercurrences occurred in the right eye, we reported the occurrence of vitreous hemorrhage after posterior vitreous detachment, which resolved spontaneously. Additional laser treatment was performed for enhancement of the panretinal photocoagulation. Moreover, we reported ocular hypertension in the right eye (max. IOP = 27 mm Hg), which was effectively controlled with hypotensive eye drops and selective laser trabeculoplasty (SLT) (Table [1](#T1){ref-type="table"}), without any documented damage to the optic nerve.

Discussion {#sec1_3}
==========

Due to its chronic nature and persistence, DME can be difficult to manage. Combined medical and even surgical procedures may be the best way to achieve DME control in patients. Use of an FAc intravitreal implant, a slow-release low-dose corticosteroid implant, is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies, and it is the only treatment available with a treatment regimen of 1 single injection for up to 36 months \[[@B11]\], which suggests a reduced treatment burden.

The patient whose case we reported is a challenge to any ophthalmologist that treats DME. Despite having good metabolic control and despite the various treatments administered, which included both laser treatment and intravitreal injections of anti-VEGF agents and short-term-efficacy corticosteroids, she had not responded sufficiently, and chronic DME over a period of about 6 years as well as progressive aggravation of her visual function were observed. Thus, an alternative treatment was required, since the right eye was the only one with potential visual function and prolonged intraretinal fluid accumulation might have caused irreversible damage resulting in permanent visual loss. In this case, the switch to an FAc intravitreal implant in the right eye appears to have been an excellent therapeutic option, with rapid resolution of the CME and a significant increase in BCVA after injection of the implant. It also allowed the patient to remain free of DME and to achieve a good functional vision of 6/10 for more than 12 months, with an acceptable and manageable safety profile.

In recent years, there have been numerous clinical studies reporting the efficacy and safety of the FAc implant in patients whose DME has been insufficiently responsive to laser therapy and intravitreal anti-VEGF agents \[[@B13], [@B14], [@B15], [@B16], [@B17]\]. As an example, Alfaqawi et al. \[[@B14]\] showed, at 12 months, a mean improvement of +8 letters from baseline and a gain of ≥15 ETDRS letters in 25% of their patients. This kind of emerging evidence has been vital for clinicians to justify the use of the FAc implant in those patients who have not responded to the first-line therapy of DME.

This case report also demonstrates the potential effectiveness of the FAc intravitreal implant in a real-world clinical setting and suggests that it should be considered if a patient does not respond optimally to other available therapies. Notably, in this case, we observed that a prior steroid response to intravitreal triamcinolone predicted a subsequent response to the FAc implant, including patient IOP outcomes. Recently, Bailey et al. \[[@B18]\] have already shown that emergent IOP-lowering medication or IOP elevation above 30 mm Hg following treatment with FAc was more frequently reported in patients with prior IOP-related events. In our case, SLT was successfully utilized in the management of ocular hypertension, which may suggest a potential role for SLT as a less-invasive treatment for the management of IOP elevation associated with FAc treatment.
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![OCT. Bilateral extensive cystoid macular edema and subfoveal neurosensory retinal detachment after laser photocoagulation (September 2009).](cop-0008-0465-g01){#F1}

![**a--f** Prior to injections (August 2011). **a--d** Retinography and fluorescein angiography. Bilateral severe diabetic macular edema with hard exudates in the right eye; there are visible scars after panretinal photocoagulation. **e**, **f** OCT. Extensive CME with huge intraretinal cysts. **g**, **h** After intravitreal triamcinolone injections (October 2011). OCT images. Right eye with few cysts and left eye with a dry macula.](cop-0008-0465-g02){#F2}

![**a** OCT. Cystoid macular edema in the right eye prior to injection of the fluocinolone acetonide implant (July 2015). **b** OCT. Dry macula of the right eye 1 month following treatment with the fluocinolone acetonide implant (October 2015). **c** Visualization of the intravitreal fluocinolone implant in the patient\'s right eye at the day of injection. **d** Graph showing the change in best corrected visual acuity (BCVA) and central macular thickness (CMT) following injection of the fluocinolone acetonide implant.](cop-0008-0465-g03){#F3}

###### 

Summary of the treatments performed for DME in the right eye of the patient

  Date          Description                                             VA      CFT[^a^](#T1F1){ref-type="table-fn"}, µm   IOP, mm Hg
  ------------- ------------------------------------------------------- ------- ------------------------------------------ -------------------------------------
                                                                                                                           
  11/2004       Incipient diabetic retinopathy diagnosed                10/10   NN                                         17
  03/2008       Moderate nonproliferative diabetic retinopathy          9/10    NN                                         14
  04/2008       Focal laser photocoagulation                                                                               
  03/2009       DME diagnosed                                           3/10    492                                        NN
  05/2009       Macular grid laser                                                                                         
  09/2009       Visit                                                   3/10    512                                        NN
  10/2009       IVTA injection                                                                                             
  11/2009       Visit                                                   4/10    302                                        18
  06/2010       Proliferative diabetic retinopathy diagnosed                                                               16
  07/2010       Panretinal photocoagulation                                                                                
  12/2010       Visit                                                   3/10    315                                        16
  05/2011       Proliferative diabetic retinopathy progression                                                             17
  06/2011       Reinforcement of panretinal photocoagulation                                                               
  08/2011       Visit                                                   1/10    664                                        14
  09/2011       IVTA injection                                                                                             14
  10/2011       Visit                                                   5/10    308                                        20
                                                                                                                           
  01/2012       Visit                                                   1/10    540                                        17
  03/2012       IVTA injection                                                                                             
  04/2012       Visit                                                   5/10    268                                        26[^b^](#T1F2){ref-type="table-fn"}
  05/2012       Visit                                                   5/10    NN                                         14
  08/2012       Visit                                                   3/10    420                                        14
  09/2012       IVTA injection                                                                                             
  02/2013       Dense cataract                                          1/10    NN                                         18
  04/2013       Cataract surgery + IVTA injection                                                                          
  05/2013       Visit                                                   5/10    287                                        18
  07/2013       Visit                                                   6/10    292                                        20
  09/2013       Visit                                                   2/10    454                                        NN
  10--11/2013   3 intravitreal injections of ranibizumab                                                                   
  12/2013       Visit                                                   5/10    270                                        NN
  02/2014       Visit                                                   4/10    480                                        NN
  04/2014       IVTA injection                                                                                             
  05/2014       Visit                                                   5/10    290                                        
                                                                                                                           
  07/2014       Visit                                                   2/10    520                                        
  09--11/2014   3 intravitreal injections of ranibizumab                                                                   
  12/2014       Visit                                                   3/10    360                                        
  01/2015       Visit                                                   1/10    458                                        
  04/2015       IVTA injection                                                                                             
  05/2015       Visit                                                   5/10    262                                        15
  07/2015       Visit                                                   2/10    488                                        23
  09/2015       Fluocinolone acetonide intravitreal implant injection                                                      
  10/2015       Visit                                                   6/10    198                                        14
  12/2015       Visit                                                   6/10    169                                        21
  03/2016       Visit                                                   6/10    167                                        27[^c^](#T1F3){ref-type="table-fn"}
  09/2016       Visit                                                   6/10    168                                        22
  10/2016       Visit                                                   6/10    NN                                         27[^d^](#T1F4){ref-type="table-fn"}
  01/2017       Visit                                                   6/10    NN                                         24[^e^](#T1F5){ref-type="table-fn"}
  03/2017       Visit                                                   6/10    208                                        18

CFT, central foveal thickness; DME, diabetic macular edema; IOP, intraocular pressure; IVTA, intravitreal triamcinolone acetonide; NN, no numbers; VA, visual acuity.

Spectral domain OCT Copernicus^®^ (Optopol) until end of 2014 and Avanti RTVue XR^®^ (Optovue) after that.

Here the patient was medicated with eye drops of timolol and dorzolamide for 2 months.

The patient started treatment with eye drops of timolol and dorzolamide.

Brimonidine was added to the topical hypotensive treatment.

The patient underwent selective laser trabeculoplasty after this visit, keeping the hypotensive eye drops.
